Chacko Lyssa N, Chen Yang K, Shah Raj J
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80045, USA.
Gastrointest Endosc. 2008 Oct;68(4):667-73. doi: 10.1016/j.gie.2008.01.025. Epub 2008 Apr 24.
Long-term outcomes of minor papilla endotherapy (MPE) in pancreas divisum are limited.
To determine the efficacy of MPE in symptomatic pancreas divisum subgroups.
This was a retrospective study of patients from an endoscopy database. The data collection instrument included preprocedure and postprocedure pain score, narcotic use, acute pancreatitis episodes, emergency department visits, and hospitalizations. A follow-up was obtained by chart review and telephone contact with a questionnaire.
A tertiary-referral center.
(1) Clinical improvement defined as a > or = 50% reduction in the evaluated data points and (2) non-MPE interventions for pain.
Between January 2000 and April 2006, 57 patients were identified. Indications were recurrent acute pancreatitis (RAP) (n = 27 [47%]), abdominal pain and chronic pancreatitis (CP) (n = 20 [35%]), abdominal pain alone (n = 8 [14%]), other (n = 2 [4%]). Successful MPE occurred in 49 of 57 patients (86%). Initial MPE entailed minor papilla sphincterotomy (n = 46), stenting without sphincterotomy (n = 2), and tamponade of bleeding (n = 1). Follow-up was obtained in 56 of 57 patients (98%) for a median of 20 months (interquartile range 12-39 months); 28 of 48 patients (58%) with successful MPE had clinical improvement: 16 of 21 (76%) with RAP, 8 of 19 (42%) with CP, and 2 of 6 (33%) with pain alone (RAP vs non-RAP; P = .019). Two patients had resolution of a dorsal-duct leak and bleeding, respectively. Twelve of 57 patients (21%) underwent 16 additional interventions for incomplete response: celiac plexus block (4), intrathecal narcotic pump (2), sphincteroplasty (7), bilateral thoracic splanchnicectomy (2), and Puestow procedure (1); 7 of 12 patients (58%) clinically improved.
This was a retrospective study.
(1) MPE is most effective in patients with pancreas divisum and with RAP with or without pancreatic ductal changes, (2) although patients with chronic pain and pancreas divisum respond poorly to MPE, the majority will have clinical improvement after additional nonendoscopic interventions for pain management.
胰腺分裂症中小乳头内镜治疗(MPE)的长期疗效有限。
确定MPE在有症状的胰腺分裂症亚组中的疗效。
这是一项对来自内镜数据库患者的回顾性研究。数据收集工具包括术前和术后疼痛评分、麻醉药物使用情况、急性胰腺炎发作次数、急诊就诊次数和住院情况。通过查阅病历和电话问卷调查进行随访。
一家三级转诊中心。
(1)临床改善定义为评估数据点减少≥50%;(2)针对疼痛的非MPE干预措施。
2000年1月至2006年4月期间,共确定57例患者。适应证包括复发性急性胰腺炎(RAP)(n = 27 [47%])、腹痛合并慢性胰腺炎(CP)(n = 20 [35%])、单纯腹痛(n = 8 [14%])、其他(n = 2 [4%])。57例患者中有49例(86%)MPE治疗成功。初始MPE包括小乳头括约肌切开术(n = 46)、未行括约肌切开术的支架置入术(n = 2)和出血填塞术(n = 1)。57例患者中有56例(98%)获得随访,中位随访时间为20个月(四分位间距12 - 39个月);48例MPE治疗成功的患者中有28例(58%)临床改善:RAP患者中21例有16例(76%)改善,CP患者中19例有8例(42%)改善,单纯腹痛患者中6例有2例(33%)改善(RAP与非RAP比较;P = 0.019)。2例患者分别解决了背侧胰管漏和出血问题。57例患者中有12例(21%)因反应不完全接受了16次额外干预:腹腔神经丛阻滞(4次)、鞘内麻醉泵置入(2次)、括约肌成形术(7次)、双侧胸交感神经切除术(2次)和Puestow手术(1次);12例患者中有7例(58%)临床改善。
这是一项回顾性研究。
(1)MPE对胰腺分裂症合并RAP且有或无胰管改变的患者最有效;(2)尽管慢性疼痛合并胰腺分裂症的患者对MPE反应不佳,但大多数患者在接受额外的非内镜疼痛管理干预后会有临床改善。